JSPR
Jasper Therapeutics, Inc.1.7100
+0.0700+4.27%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
47.85MP/E (TTM)
-Basic EPS (TTM)
-5.82Dividend Yield
0%Recent Filings
8-K
8-K
Briquilimab urticaria data mixed
Jasper Therapeutics reported Q2 2025 results, highlighting briquilimab's strong efficacy in urticaria trials—89% complete responses in high-dose BEACON cohorts and 92% in SPOTLIGHT—yet flagged an investigation into weak performance in two cohorts possibly tied to drug lot variability, with updates due late 2025. Cash stood at $39.5 million after a 50% workforce cut and program halts to prioritize urticaria, while net loss hit $26.7 million. Restructuring preserves runway but underscores development risks.
10-Q
Q2 FY2025 results
Jasper Therapeutics ramped up R&D spending in Q2 FY2025 ended June 30, 2025, with operating expenses hitting $27.1M, up 69% y/y from $16.0M, driven by $21.2M in research costs—a 88% y/y jump—fueled by briquilimab platform advances and clinical trials in CSU and CIndU. Net loss widened to $26.7M, or $1.74 per diluted share on 15.3M shares, versus $14.6M or $0.97 last year, while YTD figures show $48.0M loss or $3.16 per share against $28.3M or $2.00. Cash burned $38.3M in operations for the half, leaving $39.5M at quarter-end after $6.2M from ATM equity sales; free cash flow not disclosed in the 10-Q. Post-quarter, a 50% workforce cut aims to stretch runway by focusing on urticaria programs, halting asthma and others. Yet regulatory hurdles loom large in biotech approvals.
8-K
Jasper cuts 50% staff, refocuses
Jasper Therapeutics approved a corporate reorganization on July 8, 2025, slashing its workforce by 50% to extend cash runway while halting all clinical and preclinical programs except briquilimab for chronic urticaria. Chief Medical Officer Dr. Edwin Tucker departs August 1, with Dr. Daniel Adelman stepping in as acting CMO; severance costs hit $1.8-$2.2 million through Q3. This pivot sharpens focus on promising urticaria data, yet risks capital needs for ongoing studies.
8-K
Briquilimab excels in urticaria trials
Jasper Therapeutics unveiled promising BEACON study updates on July 7, 2025, showing briquilimab's single doses of 240mg and 360mg triggered complete responses in 89% of nine chronic spontaneous urticaria patients by week 4, with deep tryptase reductions and no severe adverse events. Yet multi-dose cohorts faltered due to a faulty drug lot, prompting an investigation, patient redosing with fresh supply, and enrollment of 10-12 more participants for Q4 2025 data. The company halted its asthma trial and SCID development while eyeing cost cuts to stretch cash. Briquilimab shines in urticaria, but delays Phase 2b to mid-2026.
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
CLDX
Celldex Therapeutics, Inc.
26.68-0.41
CRSP
CRISPR Therapeutics AG
55.97-0.28
GRCE
Grace Therapeutics, Inc.
3.34+0.10
HOTH
Hoth Therapeutics, Inc.
1.05-0.04
JBIO
Jade Biosciences, Inc.
16.04+0.79
MRKR
Marker Therapeutics, Inc.
1.27-0.12
SPRO
Spero Therapeutics, Inc.
2.27-0.02
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07
VERA
Vera Therapeutics, Inc.
48.30-0.91